XML 47 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2021

Fair Value Disclosures [Abstract]

Investments measured at fair value on recurring basis

Investments, which were measured at fair value on a recurring basis, consisted of the following:

			December 31, 2021																								December 31, 2020
			Fair Value						Fair Value Measurements Using																		Fair Value						Fair Value Measurements Using
(in millions)									Level 1						Level 2						Level 3												Level 1						Level 2						Level 3
Cash and cash equivalents:
Cash and money market funds			$	340.8					$	340.8					$	—					$	—					$	187.1					$	187.1					$	—					$	—
Restricted cash:
Certificates of deposit			3.2						3.2						—						—						3.2						3.2						—						—
Debt securities available-for-sale:
Commercial paper			204.8						—						204.8						—						82.2						—						82.2						—
Corporate debt securities			485.5						—						485.5						—						445.9						—						445.9						—
Securities of government-sponsored entities			240.9						—						240.9						—						312.9						—						312.9						—
Equity securities:
Equity securities–biotechnology industry			63.7						52.7						—						11.0						38.2						—						—						38.2
			$	1,338.9					$	396.7					$	931.2					$	11.0					$	1,069.5					$	190.3					$	841.0					$	38.2

Reconciliation of equity securities measured at fair value on recurring basis using significant unobservable inputs

The following table presents a reconciliation of equity security investments, which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3):

			Year Ended December 31,
(in millions)			2021						2020						2019
Balance at beginning of period			$	38.2					$	55.9					$	—
Purchases (1)			4.6						—						68.9
Unrealized gain (loss) included in earnings			20.9						(17.7)						(13.0)
Transfers out of Level 3 (2)			(52.7)						—						—
Balance at end of period			$	11.0					$	38.2					$	55.9

_________________________

(1) In September 2021, we purchased 0.3 million shares of Xenon's common stock, valued at $4.6 million on the date of purchase, in connection with the European Union’s approval of the clinical trial application for NBI-921352.

(2) In the fourth quarter of 2021, our equity security investment in Xenon was transferred from Level 3 to Level 1 as the associated holding period restriction expired.

X

- Definition

Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258

+ Details

Name:	us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258

+ Details

Name:	us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_FairValueDisclosuresAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration